Cerus (NASDAQ:CERS) Stock Crosses Above 200-Day Moving Average – Here’s What Happened

Cerus Corporation (NASDAQ:CERS)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.81 and traded as high as $2.61. Cerus shares last traded at $2.56, with a volume of 2,004,835 shares traded.

Wall Street Analyst Weigh In

CERS has been the subject of several research analyst reports. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. TD Cowen restated a “buy” rating on shares of Cerus in a research note on Monday, January 12th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Cerus Stock Down 1.5%

The company has a 50-day moving average of $2.30 and a two-hundred day moving average of $1.82. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.89 and a quick ratio of 1.29. The company has a market capitalization of $491.75 million, a PE ratio of -32.00 and a beta of 1.52.

Hedge Funds Weigh In On Cerus

Several large investors have recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in shares of Cerus in the fourth quarter worth $25,000. Focus Partners Advisor Solutions LLC boosted its holdings in Cerus by 65.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 19,930 shares of the biotechnology company’s stock worth $28,000 after buying an additional 7,866 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in Cerus in the 3rd quarter worth $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in Cerus in the 1st quarter worth $32,000. Finally, Aquatic Capital Management LLC bought a new stake in Cerus during the third quarter valued at about $35,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.